# Ascendis Pharma A/S (ASND)

Source: https://www.quantisnow.com/company/ASND
Generated: 2026-11-14T17:06:46.257Z

- Ticker: ASND
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2015
- SEC CIK: 0001612042
- Website: ascendispharma.com

## About

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

## Latest ASND news and filings

- 2026-11-12 21:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6787513)
- 2026-11-12 12:45 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6786348)
- 2026-11-12 12:45 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6786344)
- 2026-11-12 12:30 UTC [Earnings] [Ascendis Pharma Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/ascendis-pharma-reports-third-quarter-2026-financial-results-6786207)
- 2026-11-10 21:01 UTC [Conference Announcement] [Ascendis Pharma to Participate in the Jefferies London Healthcare Conference](https://www.quantisnow.com/insight/ascendis-pharma-to-participate-in-the-jefferies-london-healthcare-conference-6783731)
- 2026-11-06 21:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6779169)
- 2026-11-06 13:00 UTC [Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union](https://www.quantisnow.com/insight/once-weekly-transcon-cnp-navepegritide-to-receive-10-years-of-market-6778062)
- 2026-11-05 21:01 UTC [Earnings Date] [Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026](https://www.quantisnow.com/insight/ascendis-to-report-third-quarter-2026-financial-results-and-provide-6775890)
- 2026-11-05 18:10 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-ascendis-pharma-as-6775471)
- 2026-10-26 20:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6757484)
- 2026-10-26 12:00 UTC [TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years](https://www.quantisnow.com/insight/transcon-pth-palopegteriparatide-demonstrates-sustained-clinically-meaningful-improvements-in-kidney-6757024)
- 2026-10-16 18:58 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6749061)
- 2026-10-16 12:29 UTC [Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children](https://www.quantisnow.com/insight/once-weekly-transcon-cnp-navepegritide-receives-positive-chmp-opinion-for-the-6748727)
- 2026-10-14 21:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6746850)
- 2026-10-06 13:15 UTC [Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026](https://www.quantisnow.com/insight/ascendis-to-share-latest-advances-in-hypoparathyroidism-and-achondroplasia-programs-6738502)
- 2026-09-29 20:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6729157)
- 2026-09-28 20:08 UTC [SEC Form 4] [SEC Form 4 filed by Director Bienaime Jean Jacques](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-bienaime-jean-jacques-6727697)
- 2026-09-15 18:12 UTC [Analyst Downgrade] [Ascendis Pharma downgraded by Raymond James with a new price target](https://www.quantisnow.com/insight/ascendis-pharma-downgraded-by-raymond-james-with-a-new-price-6715879)
- 2026-09-14 22:00 UTC [Ascendis Announces Planned $400 Million Share Repurchase Program](https://www.quantisnow.com/insight/ascendis-announces-planned-400-million-share-repurchase-program-6715035)
- 2026-09-14 22:00 UTC [Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases](https://www.quantisnow.com/insight/ascendis-to-regain-rights-to-transcon-technology-in-metabolic-and-6715034)
- 2026-09-09 21:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6710386)
- 2026-09-09 21:04 UTC [SEC Form 4] [SVP & PAO Bodenhoff Mads exercised 3,000 units of Ordinary Shares at a strike of $110.00 and sold $810,570 worth of Ordinary Shares (3,000 units at $270.19) (SEC Form 4)](https://www.quantisnow.com/insight/svp-pao-bodenhoff-mads-exercised-3000-units-of-ordinary-shares-6710326)
- 2026-09-09 20:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6709933)
- 2026-09-09 20:01 UTC [First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026](https://www.quantisnow.com/insight/first-infant-data-from-ascendis-trial-of-once-weekly-transcon-cnp-6709895)
- 2026-09-08 20:01 UTC [Conference Announcement] [Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference](https://www.quantisnow.com/insight/ascendis-pharma-to-participate-in-the-morgan-stanley-24th-annual-6708139)
- 2026-09-07 11:00 UTC [Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026](https://www.quantisnow.com/insight/ascendis-to-share-its-latest-endocrinology-rare-disease-data-at-6707148)
- 2026-09-03 20:09 UTC [SEC Form 4] [Director Holtug Lars sold $62,335 worth of Ordinary Shares (236 units at $264.13), decreasing direct ownership by 6% to 4,000 units (SEC Form 4)](https://www.quantisnow.com/insight/director-holtug-lars-sold-62335-worth-of-ordinary-shares-236-6705128)
- 2026-08-31 20:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6699734)
- 2026-08-31 11:00 UTC [Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)](https://www.quantisnow.com/insight/ascendis-and-biomarin-enter-binding-term-sheet-for-a-global-6698996)
- 2026-08-27 12:36 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on Ascendis Pharma with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-ascendis-pharma-with-a-new-6696573)
- 2026-08-25 20:01 UTC [Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026](https://www.quantisnow.com/insight/ascendis-announces-oral-presentation-of-week-104-data-from-its-6694110)
- 2026-08-19 12:23 UTC [Analyst Coverage Initiated] [BMO Capital Markets initiated coverage on Ascendis Pharma with a new price target](https://www.quantisnow.com/insight/bmo-capital-markets-initiated-coverage-on-ascendis-pharma-with-a-6687876)
- 2026-08-19 01:02 UTC [Insider Buy] [Director Bienaime Jean Jacques bought $492,654 worth of Ordinary Shares (2,000 units at $246.33), increasing direct ownership by 222% to 2,900 units (SEC Form 4)](https://www.quantisnow.com/insight/director-bienaime-jean-jacques-bought-492654-worth-of-ordinary-shares-6687548)
- 2026-08-18 12:00 UTC [Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients](https://www.quantisnow.com/insight/eyconis-announces-initiation-of-first-in-human-clinical-trial-of-eyc-0305-in-6685886)
- 2026-08-13 20:30 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-ascendis-pharma-as-6680870)
- 2026-08-13 13:14 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6679650)
- 2026-08-13 11:55 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6679341)
- 2026-08-13 11:30 UTC [Earnings Date] [Ascendis Pharma Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/ascendis-pharma-reports-second-quarter-2026-financial-results-6679280)
- 2026-08-12 21:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascendis Pharma A/S](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascendis-pharma-as-6678577)
- 2026-08-06 20:01 UTC [Earnings Date] [Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026](https://www.quantisnow.com/insight/ascendis-to-report-second-quarter-2026-financial-results-and-provide-6668526)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ASND
- Earnings history: https://www.quantisnow.com/earnings/ASND
- Dividend history: https://www.quantisnow.com/dividends/ASND
- Insider transactions: https://www.quantisnow.com/insiders/ASND
- Options chain: https://www.quantisnow.com/options/ASND
- SEC 8-K filings only: https://www.quantisnow.com/company/ASND/8-k
- RSS and alerts for ASND: https://www.quantisnow.com/docs/rss-feeds.md